Idorsia Ltd (IDRSF)
OTCMKTS · Delayed Price · Currency is USD
4.750
-0.250 (-5.00%)
At close: Feb 10, 2026
Idorsia Revenue
Idorsia had revenue of 41.49M CHF in the quarter ending September 30, 2025, with 58.35% growth. This brings the company's revenue in the last twelve months to 232.51M, up 213.69% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
232.51M CHF
Revenue Growth
+213.69%
P/S Ratio
4.29
Revenue / Employee
357.71K CHF
Employees
650
Market Cap
1.25B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Idorsia News
- 13 days ago - Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium - GlobeNewsWire
- 15 days ago - Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America - GlobeNewsWire
- 4 weeks ago - Idorsia Ltd at JPMorgan Healthcare Conference Transcript - GuruFocus
- 4 weeks ago - Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 4 weeks ago - Idorsia Advances Fabry Disease Program With Encouraging Phase 3 Results - Nasdaq
- 4 weeks ago - Idorsia to present at J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease - GlobeNewsWire